GlassScriptPhysician profile
Barbara M Karcher
NPI 1558756387
$1,492.18
in general payments reported to CMS, 2019-2025
25 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.36 · 2020: $15.46 · 2022: $185 · 2023: $393 · 2024: $400 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205.19 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $203.79 | 2023-2025 | |
| Glaxosmithkline, LLC. | $135.17 | 2020-2025 | Boostrix, Shingrix, Arexvy |
| Amgen INC. | $127.91 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $109.21 | 2022-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $99.49 | 2022-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $80.75 | 2022-2025 | Trintellix |
| Pfizer INC. | $74.27 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.97 | 2025 | Jardiance |
| Shield Therapeutics INC | $44.54 | 2023 | Accrufer |
| Astellas Pharma US INC | $43.89 | 2023-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $37.40 | 2022-2023 | |
| Medtronic, INC. | $37.06 | 2022-2024 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $36.74 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.33 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.84 | 2024 | Yupelri |
| Exact Sciences Corporation | $21.22 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $21.14 | 2024 | Nuedexta |
| Biogen, INC. | $19.25 | 2024 | Tysabri, Vumerity |
| Stryker Corporation | $19.13 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amarin Pharma, INC. | $19.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.81 | 2025 | Airsupra |
| Lundbeck LLC | $14.78 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $13.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Karcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.